Syneron Medical Ltd.
Investor Presentation
February 2012



Syneron

CANDELA

Safe Harbor For Forward Looking Statements

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

Investment Highlights

Global leader in aesthetic devices with 35% world-wide market share[1]

Platform aesthetic company with largest worldwide sales, distribution and service network across 90 countries

Comprehensive and diverse product portfolio with leadership position in largest and fastest growing markets

Differentiated by product innovation, customer relationships and strong clinical data

~$228 million revenue[2] (29% recurring[3]); $171 million in cash (no debt)[4]; significant tax advantages

1 – Based on US publicly traded companies listed here (SLTM, CYNO, PMTI, CUTR, ZLTQ); Does not include: privately held companies, home use companies, dental companies, aesthetic topicals/ cosmeceuticals companies, foreign-exchange listed companies, etc.
2 – Trailing twelve month revenue
3 – Based on 4Q 2011 results in PAD segment
4 – December 31, 2011 Balance Sheet

Positioned to Outgrow the Industry

- Strongest industry position in largest and fastest growing Professional Aesthetic Device market segments – <u>#1 or #2 position in each market segment</u>
- Complementary products for dermatologists, plastic surgeons and non-core customers

Procedure	2013 (projected volume)	CAGR (2008 - 2013)	Syneron / Candela Products
Fractional Skin Rejuvenation	3,567,000	15.8%	eTwo, ematrix™, eprime™, fractional CO_2 innovation. Introducing CO2RE
Skin Rejuvenation	2,889,000	8.5%	
Cellulite Reduction	1,784,000	19.5%	VelaShape™, VelaShape II™, Velasmooth pro™
Hair Removal	9,365,000	13.0%	eLase with Motif™, GentleLASE PRO, GentleMax, AlexTriVantage, Vbeam Perfecta
Skin Tightening	1,226,000	21.8%	
Vascular Lesion Removal	1,003,000	9.4%	
Pigment Lesion Removal	892,000	10.2%	
Tattoo Removal	669,000	12.8%	

* Source: U.S. markets for laser, light, and energy devices 2009 Millennium Research

Unmatched Global Footprint & Distribution



- Syneron Corporate HQ
- Syneron North America HQ (Irvine, CA)
- Candela HQ (Wayland, MA)
- Syneron Regional HQ (Toronto Canada / Hong Kong)
- Direct International Sales (Australia, Canada, France, Germany, Italy, Japan, Portugal, Spain, UK, Israel and China)

- Global infrastructure provides agility and flexibility
  - Clear leader in the international market--Channel to market capability in 90 countries
  - Rapidly deploying resources to high growth markets
  - Accelerating global cross selling opportunities
- Multiple sales channels across geographies and product segments
  - Direct presence in 11 key markets
  - Direct sales enhance customer relationships, drive service revenue and increase profitability

Ultrashape Acquisition Highlights

- Worldwide market for medical devices in the body circumference reduction utilizing fat cell destruction techniques estimated at $440 M with projected annual growth of >15%. Sales of ancillary disposable products are expected to increase accordingly
- Acquired Ultrashape's non-invasive focused ultrasound fat sculpting products for $12 million cash
- Provides immediate entry into large and growing fat destructive non-invasive body sculpting market
- Approved and commercially available in Europe, Canada, Latin America and Asia
- FDA clearance expected within 18 months
- Further strengthens PAD segment product portfolio
- Highly synergistic with Syneron's existing body contouring products with focus on the core market segment
- Significant growth opportunity to distribute Ultrashape's products through Syneron's global sales and distribution channels
- Third generation product **Contour I V3** indicated for body sculpting and circumferential reduction of abdomen flanks and thighs
- Expected to be accretive by the end of 2012

The Ultrashape Advantage

- The Contour I V3 - safe and effective high intensity non-thermal focused ultrasound technology
- Ultrashape's Vertical Dynamic Focus (VDF™) allows selective destruction of fat cells in various depths of the fat tissue
  - Fat cells are destroyed via a mechanical ***non-thermal*** process
  - Treatment times are significantly shorter than other fat destructive technology
  - Highly Effective results after only one treatment
  - all areas of the body and normal to overweight patients can be treated
  - Virtually Pain free treatment
  - Great value proposition for patients and physicians alike

Fourth Quarter 2011 Highlights

- Revenue of $61.0 million, up 14% YoY
  - International revenue of $40.1 million, up 14% YoY
  - North America revenue of $20.9 million, up 15% YoY
  - Significant cross-selling revenues
  - Service and consumables represented 29% of PAD segment revenue
- Recurring service and consumable revenue down 8% YoY
  - Excluding temporary effect of restructuring that occurred at a major North American customer, consumables revenue up 54% YoY
- Gross margin of 55.0%[1(non-GAAP)], up from 53.8% in 3Q11
- Net income of $1.1 million[1(non-GAAP)], or $0.03 per share vs. net income of $3.6 million, or $0.10 per share prior year
- Operating profit in Professional Aesthetic Device business of $5.6 million[1(non-GAAP)]
- Emerging Business Units revenue of $6.0 million, up 336% YoY and representing 10% of total revenue

1 – Non-GAAP figures exclude stock-based compensation, amortization and merger related expenses, and Palomar settlement expenses and associated legal fees

Syneron

CANDELA



Thank You

To lead and drive the widespread accessibility of trustworthy aesthetic products to the general public

Syneron

CANDELA